Moreau discussed conclusions drawn from part 2 of the CASSIOPEIA trial and the need for further follow-up with bortezomib, thalidomide and dexamethasone plus maintenance daratumumab in newly diagnosed multiple myeloma.
During a discussion at ASCO 2021, Mounzer Agha, MD, talked about mitigation strategies used by the investigators from the CARTITUDE-2 trial to prevent cognitive and neuro-movement disorders commonly associated with CAR T-cell therapy.
Moreau detailed the patient characteristics of those enrolled on the CASSIOPEIA trial, which investigating bortezomib, thalidomide and dexamethasone plus daratumumab in patients with newly diagnosed multiple myeloma.
Usmani detailed the primary results from CARTITUDE-1, focusing on overall response rate and stringent complete responses.
Moreau discussed the implications of the second part of the CASSIOPEIA trial at the 2021 ASCO Annual Meeting.
Usmani discussed the common adverse events observed from CARTITUDE-1, including hematologic events and cytokine release syndrome.
Agha detailed updated findings from CARTITUDE-2 investigating cilta-cel for previously treated patients with multiple myeloma.
Subcutaneous Elranatamab had high response rates when given at or above 215 μg/kg.
Data from the MonumentTAL-1 trial detailed the benefits with the recommended phase II dose of talquetamab to treat patients with relapsed/refractory multiple myeloma.
Treatment with the off-the-shelf, full-size BCMA X CD3 bi-specific antibody appeared well tolerated with promising efficacy among patients with relapsed/refractory multiple myeloma.